Liver and kidney transplantation

Simultaneous liver–kidney transplantation is presented as the appropriate escalation for selected patients whose HCV-related liver disease has advanced beyond the safety of kidney-alone transplantation. Its significance lies in treating the renal and hepatic dimensions of a systemic infection together: Hepatitis C can injure the liver, provoke autoimmune and renal disease, and complicate dialysis, while post-transplant immunosuppression may accelerate liver disease and create additional risks for the renal graft.

Definition and Clinical Setting

Simultaneous liver–kidney transplantation is considered for a patient who has both advanced liver disease and end-stage renal disease requiring a kidney transplant. The concept appears most clearly in the management of HCV-infected candidates on the kidney waiting list. Patients with early fibrosis may remain eligible for kidney-alone transplantation under surveillance, but those whose disease progresses to early or established cirrhosis should be removed from the kidney list and referred to a liver team for consideration of simultaneous liver–kidney transplantation.

This pathway reflects the book’s broader understanding of HCV as a systemic disease rather than an isolated hepatic infection. HCV may induce renal, autoimmune, and dermatological disease, including mixed cryoglobulinemia and cryoglobulinemic glomerulonephritis. In patients with chronic kidney disease, the transplant decision therefore cannot be based only on renal replacement needs or liver enzymes; it must account for active infection, fibrosis stage, extrahepatic disease, and the likely course of liver injury under immunosuppression.

Assessment Before the Decision

The route toward simultaneous transplantation begins with establishing whether infection is active. Chronic HCV infection is defined by the combination of anti-HCV antibodies and detectable HCV RNA; antibody positivity alone does not distinguish resolved infection from ongoing infection. In kidney-transplant candidates, screening commonly begins with an enzyme immunoassay in regions of low prevalence, followed by nucleic acid testing to document viremia. In high-prevalence settings, nucleic acid testing is recommended as the initial test because a negative antibody assay cannot reliably exclude infection.

Liver staging is central because as many as one quarter of candidates with active HCV infection have advanced fibrosis on liver biopsy despite well-compensated disease and no obvious clinical suspicion. Noninvasive tools, including biochemical scores and FibroScan assessment of liver stiffness, may reduce the need for biopsy and support longitudinal follow-up, but the KDIGO Workgroup recommended percutaneous liver biopsy for HCV-infected patients being considered for kidney transplantation because no noninvasive test then offered equivalent accuracy and reliability.

The decision is also shaped by extrahepatic disease. Mixed cryoglobulinemia, for which HCV is the major cause, can produce purpura, arthralgias, neuropathy, hypocomplementemia, and kidney disease. Cryoglobulinemic glomerulonephritis may present with proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, or nephrotic syndrome. These manifestations can precede overt renal disease by years, so the evaluation for a combined transplant must recognize that a patient’s renal failure may be part of the infection’s broader immunologic pathology.

Waiting-List Surveillance and Escalation

Kidney waiting-list management is not passive. In some areas of the United States, deceased-donor waiting times approach five to seven years, creating a prolonged interval in which HCV-related liver disease may progress. Patients who remain viremic require continuing assessment to ensure that they remain suitable for kidney-alone transplantation. The recommended monitoring is tied to fibrosis stage: patients with Metavir stage 1 or 2 fibrosis should undergo repeat liver biopsy every five years, whereas those with stage 3 fibrosis should be rebiopsied after three years and watched more closely.

The contrast between waiting-list and post-transplant biopsies underscores the danger of delay. Among thirteen patients who underwent repeat biopsy while still awaiting transplantation, eight, or 62 percent, showed worsening liver histology. By comparison, only seven of thirty-one, or 23 percent, showed interval worsening on follow-up biopsies obtained after transplantation. These figures do not make transplantation risk-free, but they show why ongoing reassessment matters: the waiting period itself can become a period of advancing hepatic injury.

Patients who achieve a sustained virologic response before transplantation should undergo nucleic acid testing at least annually to confirm that the response persists. Relapse requires hold status and referral to a hepatologist for possible retreatment. Patients who remain viremic should likewise receive annual evaluation for progression. Once cirrhosis is established, kidney-alone transplantation is no longer treated as the default route; referral for simultaneous liver–kidney transplantation becomes the appropriate next consideration.

Risks, Benefits, and Transplant Context

The rationale for a combined procedure is inseparable from the hazards of post-transplant immunosuppression. HCV infection can progress more rapidly in the setting of immunosuppressive therapy, while interferon given after kidney transplantation may threaten the renal graft through acute rejection. This creates a difficult therapeutic sequence: viral eradication before transplantation may be desirable, but treatment is toxic and may be difficult in patients with end-stage renal disease; postponing treatment may leave the patient exposed to progressive liver disease; and treatment after kidney transplantation can jeopardize graft function.

Therapy itself imposes a substantial burden. Interferon-based treatment may cause flu-like symptoms, fever, fatigue, headache, myalgia, arthralgia, anemia, neutropenia, depression, and anxiety. Toxicity leads to dose reduction in roughly 35–42 percent of patients and discontinuation in about 30 percent. For a patient already receiving long-term dialysis, these effects can compound an existing burden of fatigue, depression, and reduced quality of life. Dialysis patients with HCV-related liver disease are often asymptomatic from the liver perspective, while fatigue and cognitive impairment are common regardless of HCV status; the apparent quietness of hepatic disease therefore cannot be mistaken for absence of risk.

The combined-transplant decision must also consider survival and the consequences of renal disease. HCV infection is associated with increased mortality among patients with end-stage renal disease on dialysis, although observational evidence regarding cardiovascular mortality is not uniform. In one dialysis study, HCV viremia was independently associated with increased aortic stiffness, while another meta-analytic estimate found no significant unadjusted association with cardiovascular-related mortality. HCV-positive dialysis patients also showed lower mental quality-of-life scores, with depression, diagnostic labeling, fatigue, cognitive symptoms, and the demands of hemodialysis all potentially contributing. These factors make the transplant pathway a question of lived health as well as organ survival.

Pathological and Institutional Significance

After renal transplantation, HCV-infected recipients remain vulnerable to immune complex-mediated glomerulonephritis. De novo membranoproliferative glomerulonephritis has been described in HCV-infected renal allograft recipients, including cases associated with type II mixed cryoglobulinemia. Clinical manifestations may include hypertension, microhematuria, proteinuria, renal dysfunction, and nephrotic syndrome. Renal biopsy can show mesangial proliferation, double contours, and IgM and C3 deposits; electron microscopy may be needed to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy, and the two lesions may coexist.

This renal pathology helps explain why combined transplantation is not merely a technical solution to two unrelated organ failures. HCV can contribute simultaneously to hepatic fibrosis, circulating immune-complex disease, and injury within a renal allograft. The book places these clinical choices within a wider institutional history: KDIGO identified HCV as a major nephrology, dialysis, and transplantation issue and produced a comprehensive clinical practice guideline addressing prevention, diagnosis, evaluation, and treatment in chronic kidney disease. Simultaneous liver–kidney transplantation consequently functions as both a treatment option and a boundary marker, identifying the point at which progressive HCV-related liver disease makes kidney-alone transplantation insufficient.